The activation peptide of coagulation factor IX and X serves as a high affinity receptor to cationic ligands

Thrombosis and Haemostasis

Volumn 110, Issue 3, 2013, Pages 620-622

  Griessner, Andreas ^a,b   Zögg, Thomas ^a   Brandstetter, Hans ^a  

^a UNIVERSITY OF SALZBURG   (Austria)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENZAMIDINE; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9A; CATION; CD11B ANTIGEN; ENZYME PRECURSOR; LIGAND;

BINDING AFFINITY; BLOOD CLOTTING; LETTER; PRIORITY JOURNAL; RECEPTOR AFFINITY;

EID: 84883257823     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-01-0051     Document Type: Letter

References (13)

1. Lenting PJ, ter Maat H, Clijsters PP, et al. Cleavage at arginine 145 in human blood coagulation factor IX converts the zymogen into a factor VIII binding enzyme. J Biol Chem 1995; 270: 14884-14890.
2. Bode W, Huber R. Induction of the bovine trypsinogen-trypsin transition by peptides sequentially similar to the N-terminus of trypsin. FEBS Lett 1976; 68: 231-236.
3. Altieri DC, Etingin OR, Fair DS, et al. Structurally homologous ligand binding of integrin Mac-1 and viral glycoprotein C receptors. Science 1991; 254: 1200-1202.
4. Iino M, Takeya H, Nishioka J, et al. The role of human factor X activation peptide in activation of factor X by factor IXa. J Biochem 1994; 116: 335-340.
5. Johansson L, Karpf DM, Hansen L, et al. Activation peptides prolong the murine plasma halflife of human factor VII. Blood 2011; 117: 3445-3452.
6. Gabriel B, Stubbs MT, Bergner A, et al. Design of benzamidine-type inhibitors of factor Xa. J Med Chem 1998; 41: 4240-4250.
7. Renatus M, Bode W, Huber R, et al. Structural mapping of the active site specificity determinants of human tissue-type plasminogen activator. Implications for the design of low molecular weight substrates and inhibitors. The J Biol Chem 1997; 272: 21713-21719.
8. Zogg T, Brandstetter H. Structural basis of the cofactor-and substrate-assisted activation of human coagulation factor IXa. Structure 2009; 17: 1669-1678.
9. Hopfner KP, Brandstetter H, Karcher A, et al. Converting blood coagulation factor IXa into factor Xa: dramatic increase in amidolytic activity identifies important active site determinants. EMBO J 1997; 16: 6626-6635.
10. Iijima K, Murakami M, Kimura O, et al. A dysfunctional factor X (factor X Kurayoshi) with a substitution of Arg 139 for Ser at the carboxyl-terminus of the light chain. Thromb Res 2001; 101: 311-316.
11. Kim DJ, Thompson AR, Nash DR, et al. Factors XWenatchee I and II: compound heterozygosity involving two variant proteins. Biochim Biophys Acta 1995; 1271: 327-334.
12. Kasai K, Ishii S. Studies on the interaction of immobilized trypsin and specific ligands by quantitative affinity chromatography. J Biochem 1978; 84: 1061-1069.
13. Bergman DA, Winzor DJ. Quantitative affinity chromatography: increased versatility of the technique for studies of ligand binding. Analyt Biochem 1986; 153: 380-386.